Effectiveness of full mRNA vaccinations to prevent COVID-19 among immunocompromised patients receiving tixagevimab-cilgavimab as pre-exposure prophylaxis–authors’ response

Benzer Materyaller

• Effectiveness of full mRNA vaccinations to prevent COVID-19 among immunocompromised patients receiving tixagevimab-cilgavimab as pre-exposure prophylaxis–authors’ response
  Yazar:: Pao-Yu Chen, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-10-01)
• Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
  Yazar:: Andrea Lombardi, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-05-01)
• SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
  Yazar:: David Totschnig, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-10-01)
• Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
  Yazar:: Jassada Buaboonnam, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-12-01)
• Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
  Yazar:: Juthaporn Cowan, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-09-01)